IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE

Objective: About 25% of Acute Lymphoblastic Leukemia (ALL) express T-cell antigens which being considered a predictive of high-risk group. This study was conducted to find out the immunophenotypic characteristics of T-cell Acute Lymphoblastic Leukemia (T-ALL) in young and adult Iraqi patients. Also,...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulsalam Al-Ani, Alaadin Sahham Naji, Luma Essa Hamodi, Alaa Fadhil Alwan
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137925001506
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850081009557569536
author Abdulsalam Al-Ani
Alaadin Sahham Naji
Luma Essa Hamodi
Alaa Fadhil Alwan
author_facet Abdulsalam Al-Ani
Alaadin Sahham Naji
Luma Essa Hamodi
Alaa Fadhil Alwan
author_sort Abdulsalam Al-Ani
collection DOAJ
description Objective: About 25% of Acute Lymphoblastic Leukemia (ALL) express T-cell antigens which being considered a predictive of high-risk group. This study was conducted to find out the immunophenotypic characteristics of T-cell Acute Lymphoblastic Leukemia (T-ALL) in young and adult Iraqi patients. Also, to determine the association of treatment outcome with the immunophenotype and the treatment regimen used. Methodology: The study was conducted using the laboratory data of the Central Flowcytometry Department at Baghdad Medical City between 7 January 2019 and 3 May 2020. The immunophenotypic records revealed 35 young and adult patients (age of 14-year or older) with T-ALL. The patients were classified into early (immature) T-cell Precursor (ETP) and Mature T-cell Precursor (MTP). Correlation of the patients’ outcome according to age, gender, and immunophenotypic expressions with the type of therapy used were evaluated. Results: Thirty-five patients were diagnosed with T-ALL with a mean age of 28.1±12.3, and 74.3% were males. The stratification of patients according to the stage of leukemic T-cells maturation showed more frequent mature phenotype (cortical and medullary) than the immature (68.6% vs. 31.4%). The MTP markers expression showed a statistically significant higher rate in patients aged < 20-year (p = 0.03) or male (p = 0.01). Most patients received hyperCVAD 26 (74.3%) protocol, and UKALL was administered in the remaining (25.7%). Remission was achieved in 82.9%, while 11.4% failed to respond and 8.7% died during induction. Remission was maintained in 54.3% with 5-months of median follow-up, and relapse was found in 11.4%. The Overall Survival (OAS) at one year was 55%, with a mean survival of 13.8+1.7 months without an association with the type of therapy, subtype of T-cell, and myeloid antigenic expression. Despite a higher remission rate and lower death rate among UKALL group compared to HyperCVAD, the difference is non-significant (p = 0.81). The better response of MTP compared to ETP lineage was the only significant value with the outcome (p = 0.045). Conclusion: T-ALL is more commonly encountered in males. Remission was maintained in more than half of the patients with a better response and survival of the patients with MTP than those with the ETP subtype. The outcome was not affected by age, gender, or the treatment protocol.
format Article
id doaj-art-08e28e0955c440cc8dac413bd3ec355e
institution DOAJ
issn 2531-1379
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Hematology, Transfusion and Cell Therapy
spelling doaj-art-08e28e0955c440cc8dac413bd3ec355e2025-08-20T02:44:50ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-07-014710388210.1016/j.htct.2025.103882IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCEAbdulsalam Al-Ani0Alaadin Sahham Naji1Luma Essa Hamodi2Alaa Fadhil Alwan3College of Medicine, University of Anbar, IraqiCollege of Medicine, University of Anbar, IraqiCollege of Medicine, Baghdad University, IraqiDepartment of Pharmacy, Al-Turath University, Baghdad, IraqiObjective: About 25% of Acute Lymphoblastic Leukemia (ALL) express T-cell antigens which being considered a predictive of high-risk group. This study was conducted to find out the immunophenotypic characteristics of T-cell Acute Lymphoblastic Leukemia (T-ALL) in young and adult Iraqi patients. Also, to determine the association of treatment outcome with the immunophenotype and the treatment regimen used. Methodology: The study was conducted using the laboratory data of the Central Flowcytometry Department at Baghdad Medical City between 7 January 2019 and 3 May 2020. The immunophenotypic records revealed 35 young and adult patients (age of 14-year or older) with T-ALL. The patients were classified into early (immature) T-cell Precursor (ETP) and Mature T-cell Precursor (MTP). Correlation of the patients’ outcome according to age, gender, and immunophenotypic expressions with the type of therapy used were evaluated. Results: Thirty-five patients were diagnosed with T-ALL with a mean age of 28.1±12.3, and 74.3% were males. The stratification of patients according to the stage of leukemic T-cells maturation showed more frequent mature phenotype (cortical and medullary) than the immature (68.6% vs. 31.4%). The MTP markers expression showed a statistically significant higher rate in patients aged < 20-year (p = 0.03) or male (p = 0.01). Most patients received hyperCVAD 26 (74.3%) protocol, and UKALL was administered in the remaining (25.7%). Remission was achieved in 82.9%, while 11.4% failed to respond and 8.7% died during induction. Remission was maintained in 54.3% with 5-months of median follow-up, and relapse was found in 11.4%. The Overall Survival (OAS) at one year was 55%, with a mean survival of 13.8+1.7 months without an association with the type of therapy, subtype of T-cell, and myeloid antigenic expression. Despite a higher remission rate and lower death rate among UKALL group compared to HyperCVAD, the difference is non-significant (p = 0.81). The better response of MTP compared to ETP lineage was the only significant value with the outcome (p = 0.045). Conclusion: T-ALL is more commonly encountered in males. Remission was maintained in more than half of the patients with a better response and survival of the patients with MTP than those with the ETP subtype. The outcome was not affected by age, gender, or the treatment protocol.http://www.sciencedirect.com/science/article/pii/S2531137925001506
spellingShingle Abdulsalam Al-Ani
Alaadin Sahham Naji
Luma Essa Hamodi
Alaa Fadhil Alwan
IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
Hematology, Transfusion and Cell Therapy
title IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
title_full IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
title_fullStr IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
title_full_unstemmed IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
title_short IMMUNOPHENOTYPIC CHARACTERISTICS AND TREATMENT OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS; AN IRAQI CENTER EXPERIENCE
title_sort immunophenotypic characteristics and treatment outcome of t acute lymphoblastic leukemia in adults an iraqi center experience
url http://www.sciencedirect.com/science/article/pii/S2531137925001506
work_keys_str_mv AT abdulsalamalani immunophenotypiccharacteristicsandtreatmentoutcomeoftacutelymphoblasticleukemiainadultsaniraqicenterexperience
AT alaadinsahhamnaji immunophenotypiccharacteristicsandtreatmentoutcomeoftacutelymphoblasticleukemiainadultsaniraqicenterexperience
AT lumaessahamodi immunophenotypiccharacteristicsandtreatmentoutcomeoftacutelymphoblasticleukemiainadultsaniraqicenterexperience
AT alaafadhilalwan immunophenotypiccharacteristicsandtreatmentoutcomeoftacutelymphoblasticleukemiainadultsaniraqicenterexperience